In 2022, the Biden Administration implemented Medicare drug price negotiations under the Inflation Reduction Act (IRA), reigniting political debate over how to address the rising cost of prescription drugs in the United States. At the center of this contentious issue is whether federal intervention can effectively challenge the pharmaceutical industry’s long-standing dominance over pricing. This issue is highly relevant to American politics as it highlights the anti-majoritarian features embedded in the U.S pollical system. The ongoing tensions between the strong public demand for affordable healthcare and overarching influence of corporate lobbying on legislative decision-making, reflects the core concepts of public opinion and interest groups. The analysis will examine how industry lobbying shapes healthcare policy outcomes and restrict congressional ability to act aligned with public preference. Despite an overwhelming public support for lowering prescription drug prices, the limited impact of reforms such as the IRA reveals the presence of anti-majoritarian forces such as powerful interest groups and institutional barriers in Congress that limit the government’s ability to enact policies that reflect majority preference leading to a weakened democratic responsiveness in healthcare policy.
The power of pharmaceutical lobbying and campaign financing reflects an anti-majoritarian feature of American politics, where specific corporate and economic interests often outweigh broad public preferences. The pharmaceutical industry spent over $739 million on federal lobbying in 2023 (OpenSecrets, 2023). By being the top spending sector for both federal and state lobbying in 2023, the “Big Pharma” industry ensured consistent influence over both parties. Research from JAMA Health Forum (Rome et al., 2023) finds that pharmaceutical industry pressure helped narrow the scope of Medicare drug price negotiations under the Inflation Reduction Act. Through federal lobbying and campaign financing, the industry can constrain attempts to reduce prices leading to limitation of any reform’s reach. This power dynamic illustrates how interest group politics and elite influence can distort majority representation resulting in an anti-majoritarian outcome where policymaking favors the few over the many. Beyond the dominant influence of interest groups, structural constraints within Congress further deepen the anti-majoritarian outcomes and create additional roadblocks for meaningful reform.
Institutional barriers within Congress such as the Senate filibuster and partisan polarization operate as anti-majoritarian mechanisms that allow a minority to block policies supported by a majority of Americans. The filibuster enables a minority of senators to prevent votes on major reforms (Backer, 2012). The filibuster presents as an institutional barrier that has become a weaponized tool for legislative gridlock utilized to undermine majority rule for lower drug prices. Surveys from the Pew Research Center show strong bipartisan public support for reduced prescription drug prices nationwide (Sparks et al., 2024). In a 2024 survey, 73% of voters (68% of democrats and 75% of republicans) across partisan lines support stronger government regulation of prescription drug prices. However, partisan polarization in Congress deepens this problem by turning drug pricing reform into a political battle under the umbrella of healthcare reform negotiations post Obamacare era. For example, in 2023 alongside Senator Mitch McConnel, many GOP lawmakers framed the reform on drug prices as “socialism” to sway lawmakers to oppose reform and instead restrict them to partisan politics (Congressional Record, 2023). These institutional barriers exemplify how institutional design and partisanship can limit democratic responsiveness and sustain policy outcomes that benefit elite interests of industries such as the health sector.
The dominant presence of rising prescription drug prices highlights how structural and political anti-majoritarian features shapes American healthcare policymaking. The substantial influence of interest groups and procedural barriers prevents Congress from enacting reforms favored by the majority of voters. This illuminates a critical tension between the democratic ideals of our nation and realities of U.S legislative power. Others argue that institutional restrictions and interest group dynamics present a safeguard for pharmaceutical innovation and can prevent harsh decisions in policy making. However, these claims do not shrink the urgent need in tackling a system where powerful actors such as "Big Pharma" can essentially overrule popular will of the people. The escalation of drug costs has brought an additional pressure on the working class in American households, and we are presented with a challenge to hold policy makers accountable to democratic will while still listening to experts from the industry. Without impactful reforms through policy making, Americans face a disparity between theirs needs and what the government can simply deliver in the era of political polarization.
References
Backer, J. (2012, March 1). Filibuster Report Shows Increased Government Gridlock | Brennan Center for Justice. Www.brennancenter.org. https://www.brennancenter.org/our-work/analysis-opinion/filibuster-report-shows-increased-government-gridlock
Congressional Record: Proceedings and Debates of the 118th. (2023). U.S Congress. https://www.congress.gov/118/crec/2023/09/07/169/144/CREC-2023-09-07.pdf
Grace Sparks, Ashley Kirzinger, Alex Montero, Isabelle Valdes, and Liz Hamel, Sparks, G., Kirzinger, A., Montero, A., Valdes, I., & Hamel, L. (2024, October 4). Public Opinion on Prescription Drugs and Their Prices | KFF. KFF. https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/
Massoglia, A. (2024, January 26). State and federal lobbying spending tops $46 billion after federal lobbying spending broke records in 2023 - OpenSecrets News. OpenSecrets News. https://www.opensecrets.org/news/2024/01/state-and-federal-lobbying-spending-tops-46-billion-after-federal-lobbying-spending-broke-records-in-2023
Rome, B. N., Nagar, S., Egilman, A. C., Wang, J., Feldman, W. B., & Kesselheim, A. S. (2023). Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022. JAMA Health Forum, 4(1), e225218. https://doi.org/10.1001/jamahealthforum.2022.5218
No comments:
Post a Comment